|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> In APP/PS1 transgenic mice and Aβ treated microglia, the interaction between HSP90 and PPARγ were analyzed by western blot.
|
30128052 |
2018 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
10<sup>6</sup> MSC were injected into APP/PS1 mice via the tail vein and histological analysis was performed for microglia and amyloid (pE3-Aβ) plaque numbers, glial distribution and pE3-Aβ plaque size.
|
26918424 |
2017 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
8-month-old female wild type (WT) and APP/PS1 mice were also administered daily NaCl or LiCl for 21 days, which was followed by cognitive assessment by novel object recognition and water maze, and measurement of soluble Aβ<sub>42</sub>, plaque-associated Aβ<sub>42</sub>, and brain efflux of <sup>125</sup>I-Aβ<sub>42</sub>.
|
29545118 |
2018 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid-beta (Abeta) the primary component of the senile plaques found in Alzheimer's disease (AD) is generated by the rate-limiting cleavage of amyloid precursor protein (APP) by beta-secretase followed by gamma-secretase cleavage.
|
15452128 |
2004 |
|
Amyloidosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Amyloid is mainly composed by amyloid-beta (A(beta)) peptides, which are derive from processing of the beta-amyloid precursor protein (APP), better named amyloid-beta precursor protein (A(beta)PP), by secretases.
|
15983050 |
2005 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid β peptide is generated from the sequential protease cleavage of the amyloid precursor protein (APP).
|
21177866 |
2011 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions.
|
21880397 |
2012 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid β (Aβ) peptides originating from amyloid precursor protein (APP) in the endosomal-lysosomal compartments play a critical role in the development of Alzheimer's disease (AD), the most common type of senile dementia affecting the elderly.
|
25939386 |
2015 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid-β (Aβ) is derived from the proteolytic processing of amyloid precursor protein (APP), and the deposition of extracellular Aβ to form amyloid plaques is a pathologic hallmark of Alzheimer's disease (AD).
|
31373844 |
2019 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
APP and beta-amyloid were expressed in neurons and to a lesser extent in astrocytes.
|
17712316 |
2008 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells.
|
17726461 |
2008 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid precursor protein (APP)/Presenilin 1 (PS1) transgenic mice, in which the orexin gene is knocked out, showed a marked decrease in the amount of Aβ pathology in the brain with an increase in sleep time.
|
25422493 |
2014 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
β-Amyloid peptide (Aβ) plaques are a cardinal neuropathologic feature of Alzheimer disease (AD), yet more than one-third of apolipoprotein E ε4 (APOE4) noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia may not meet positron emission tomographic criteria for significant cerebral amyloidosis.
|
26302353 |
2015 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid precursor protein (APP), a key molecule of Alzheimer disease, is metabolized in 2 antagonist pathways generating the soluble APP alpha (sAPPα) having neuroprotective properties and the beta amyloid (Aβ) peptide at the origin of neurotoxic oligomers, particularly Aβ1-42.
|
29032190 |
2018 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid precursor protein (APP) is processed along the amyloidogenic pathway by the β-secretase, BACE1, generating β-amyloid (Aβ), or along the nonamyloidogenic pathway by α-secretase, precluding Aβ production.
|
30545942 |
2019 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amyloid precursor protein (APP) processing plays an important role in Aβ production, which initiates synaptic and neuronal damage.
|
30622228 |
2019 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
APP/PS1 mice also exhibited higher amyloid-β40 and amyloid-β42 in their cortex, accumulation of mitochondria APP in their cortex, and presented an altered oxidative state in their brain.
|
31016475 |
2019 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
APP plays a greater role in AD pathogenesis than its role as the precursor for Aβ peptides: both the abnormal cleavage of APP leading to Aβ peptide accumulation and the disruption of APP physiological functions contribute to AD pathogenesis.
|
31039414 |
2019 |
|
Amyloidosis
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology.
|
16906128 |
2006 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accumulation and deposition of beta-amyloid peptide, a major constituent in neuritic plaques are hallmarks of Alzheimer's disease (AD) and AD-related neurodegenerative diseases. beta-Amyloid (Abeta) is derived from the proteolytic cleavage of amyloid precursor protein (APP), a transmembrane protein present in three major isoforms in brain comprising 695, 751 and 770 amino acids, respectively.
|
19093876 |
2009 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, spinosin reduced Aβ<sub>1-42</sub> production by impacting the procession of APP.
|
31791116 |
2019 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Administration of anti-IL17 for 5 months, starting at the age of 7 months, partially improved the cognitive abilities of the TS mice, reduced the expression of several pro-inflammatory cytokines and the density of activated microglia and normalized the APP and Aβ<sub>1-42</sub> levels in the hippocampi of the TS mice.
|
29758264 |
2018 |
|
Amyloidosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After 7 months of dietary intervention, we found that fish oil supplementation improved behavioral performance, alleviated brain beta-amyloid (Aβ) plaque burden, and attenuated the oxidative stress in APP/PS1 mice by increasing cortical GSH content and total antioxidant capacity, as well as by decreasing MDA level.
|
29656360 |
2018 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alternative processing of the amyloid precursor protein by β-secretase also generates the Aβ<sub>11- x</sub> species.
|
30582328 |
2019 |
|
Amyloidosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alternatively, APP can be cleaved by α-secretase within the Aβ domain to release soluble APPα and preclude Aβ generation.
|
21214928 |
2011 |